diseases, such as cancer, diabetes and heart disease, are caused by many genes and environmental factors and their interactions, progress in unravelling genetic risk factors has been slow and tedious. However, common patterns of genetic variation revealed by the International Haplotype Map (HapMap) project are now the basis for lower cost and more efficient genomics technologies. 3, 4 Comprehensive analyses of common variation in the human genome in association with specific diseases in case-control or cohort studies are commonly called genomewide association (GWA) studies. Such studies typically measure sets of special DNA 'tagging' single nucleotide polymorphisms (SNPs) identified in the HapMap project, enriched with nonsynonymous and 'quasirandom' SNPs, as well as SNPs in evolutionary conserved regions of the genome. Available analytical platforms allow testing for several hundred thousand SNPs (e.g. from 100K to 675K). Although the tested SNPs represent less than one-tenth of all known SNPs, they are in strong linkage disequilibrium with 80-90% of all known SNPs, and therefore achieve high coverage of common variants of the human genome.
It is more debatable whether rare genetic variants are properly covered. 5 As the cost of high-throughput genotyping decreases exponentially, studies performing genome-wide analysis of thousands of individuals are becoming increasingly feasible. These studies will expand the search for genetic risk factors for complex human diseases on an unprecedented scale. 6, 7 Certainly, there is increasing excitement and expectations that GWA approaches will produce disease susceptibility findings such as we have seen recently with age-related macular degeneration, 8 diabetes type II 9 and prostate cancer. 10 In this commentary, we examine the implications of GWA studies for the synthesis and interpretation of associations between single genetic variants and various complex diseases. In particular, we focus on consistently replicated but weak associations (i.e. risk ratios (RR) typically <1.5). Because we expect many gene-disease associations to have small effect sizes and fewer with larger effect sizes, 11, 12 even if they are biologically meaningful, weak true effects are difficult to distinguish from spurious effects caused by methodological biases. Thus, standards for the synthesis and interpretation of consistent but weak associations are essential tools for the imminent, large-scale epidemiological 'fishing expedition' in the human genome.
Most human genome epidemiology studies still report just one or a few gene-disease associations
Although large GWA studies are now gearing up for various diseases, [13] [14] [15] most published gene-disease associations are based on case-control studies assessing just one or a few candidate genes with a postulated role in pathogenesis. For example, as of November 21, 2006 , the online CDC database 16 of published epidemiological studies of human genes contained more than 25 000 publications; of these, 84% reported analyses of one or a few (not more than five) specific genetic variants. 17 As we discuss subsequently, many methodological issues remain in the analysis and reporting of single gene-disease associations. Even in studies using GWA methods, typically only a few associations survive the process of replication.
Effects of individual genetic variants are expected to be small, even if they are biologically meaningful is not possible to assess how likely this scenario is to occur for the majority of common diseases and whether or not it will be consistent with observed patterns of familial aggregation and heritability estimates from these studies. In more complex scenarios, interactions beyond the multiplicative model may be more important and marginal effects may well be tiny. A very strong association that is present in only a small subgroup of the population, defined by the presence of other genetic and environmental factors, can be severely diluted towards the null if these other factors were not specifically measured in the study. 25, 26 As the combined prevalence of these interacting risk factors becomes less frequent in the population, the 'average' or marginal effect-obtained from crude analysis-for each genetic variant approaches the null. For example, even a gene-disease association with a RR of 100 will have an observed RR of only 1.1, if the combination of factors required to complete a sufficient cause occurs in just 1/1000 people. 25 We recently analysed results of 50 meta-analyses (based on a total of 752 studies) that reported statistically significant summary gene-disease associations. In these meta-analyses, the median odds ratio (OR) was 1.43, with an inter-quartile range (IQR) of 1.28-1.65. 27 The true 'average' effects could be even smaller if bias exaggerated some of the results. One of the most consistently replicated but weak associations in genetic epidemiology, is that of bladder cancer with the NAT2 genotypes associated with the slow acetylator phenotype. Garcia-Closas et al. 28 reported on a meta-analysis of 31 studies of NAT2 and bladder cancer, including a total of 5091 cases and 6501 controls. The summary RR for NAT2 slow acetylators compared with rapid/intermediate acetylators was 1.4 (1.2-1.6; P < 0Á0001). The consistency of this association across numerous studies suggests that it reflects more than mere bias; however, its small size suggests that other unmeasured, underlying interactions among genes and environmental exposures also have a role. Although interaction effects abound in the literature, most are derived from small studies that are underpowered even for detecting main effects, suggesting that they may be the result of post hoc analysis with little chance of replication. 29 Among NAT2 slow acetylators, the consistent finding of higher bladder cancer risk in cigarette smokers than in never-smokers bolsters the case for true interaction. Case-only meta-analyses provided support for an interaction between NAT2 and smoking (P for interaction 0.009). 28 But wait! How will we find such needles in the haystack?
It will be exceedingly difficult from individual studies to distinguish small effects that are valid and biologically meaningful from those arising spuriously from the methodological problems that are known to plague the field of genetic association studies. Many of these problems have been described and quantified for individual studies, 30, 31 and for meta-analyses; 31 they include frank biases as well as the inherent complexity of the task at hand. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Biases include significance-chasing (including publication bias, selective analysis and reporting biases), confounding by population stratification, faulty selection of subjects for comparisons, differences in storage and genetic analysis of samples collected from cases and controls, genotyping errors, deviations from Hardy-Weinberg equilibrium, linkage disequilibrium issues and misclassification of exposures and outcomes. Other inherent problems include presence of undetected gene-gene and gene-environment interactions, limited sample size and statistical power and type I errors (false positive associations). All of these issues have been reviewed previously and will not be discussed further, except to point out that type I errors are particularly relevant to the conduct of GWA studies. A large search among hundreds of thousands of genetic variants can be expected by chance alone to find thousands of false positive signals (RRs significantly different from 1.0). Many approaches to this problem have been proposed, including Bonferroni adjustment for multiple comparisons, Bayesian inference based on prior probabilities, and more exploratory methods such as data visualization, multi-dimensionality reduction and neural network analyses. [44] [45] [46] While these methods may facilitate the detection of true associations, they are likely to greatly increase the number of false positive associations as well. Perhaps a good summary of the prevailing notion in the genetic association field is the recent editorial by Duncan Thomas.
He states: 'Clearly, the next few years should be an exciting time as GWA studies get under way . . . The interpretation of the mass of data that will result can be expected to keep investigators and pundits entertained long into the future'. 6 Perhaps the process of careful replication will help 'average' out the biases, but a prolonged cycle of initial positive, reported findings and subsequent refutation could consume a great deal of energy and resources. Therefore, we believe that more systematic attempts at epidemiological data integration and interpretation in the era of GWA studies need to be developed.
Synthesis and interpretation of the evidence on consistent but weak associations
Recognizing methodological challenges in the field of genetic associations, the Human Genome Epidemiology Network (HuGENet) was founded in 1998 as an open, global collaboration of individuals and organizations committed to creating the knowledge base on genetic variation and human diseases. Recently, the collaboration has undertaken a number of steps to move this rather difficult field forward. 47, 48 A 'network of networks' of investigators has been created to share best practices, tools and methods for analysis of associations between genetic variation and common diseases. 49 A 'road map' was published in January 2006 to define near-term plans for HuGENet and the networks. These include developing consensus guidelines for reporting results of genetic association studies; augmenting published associations with unpublished data by promoting publication of 'negative' studies and collaboration on comprehensive analyses within investigator networks; expanding systematic HuGE reviews with metaanalyses of individual-level data and prospective meta-analyses; and developing field synopses that will offer regularly updated overviews online and in selected journals. 50 55 but only in a limited way in the field of genetic association. 55 Although none of the nine criteria (including strength of association) are absolute, the question of causal interpretation of genetic associations is of timely interest. By creating the opportunity for millions of comparisons, GWA might be expected to generate an outpouring of false positive results. However, by its very nature, GWA may also supply a definitive solution to the problem of selective reporting, which is not limited to genetic epidemiology. Typically, epidemiological studies target only a few risk factors at a time and only selected findings are published. In theory, GWA studies could collect information simultaneously on a very large number of genetic variants and make the entire database transparent and available online. 7 One important near-term activity for HuGENet is developing a systematic approach to assessing cumulative evidence and inferring causality for genetic associations. In a recent commentary, one of us proposed a schema (Table 2) for qualitative scoring on five 'axes,' including effect size, replication, protection from bias, biological plausibility and relevance to medicine or public health. 57 This schema has much in common with the criteria, guidelines or viewpoints discussed earlier but will need to be further modified based on accumulated experience from ongoing GWA efforts (see Table 2 for comments). For example, in this schema, 'weak' associations (RRs <2) are viewed as least credible, yet we can expect most true associations to fall below this criterion. Indeed, many may have relative risks <1.2, in the range where very large sample sizes are needed (tens of thousands of cases). Under this scenario, the analytical ability of epidemiological methods will break down, even with limited bias. For example, a recent GWA-based discovery of a genetic variant that increases the risk of obesity 1.22-fold has not been replicated consistently. 15 How credible can this association be and how large a sample size do we need to validate such an association, even if it is true? Replication of evidence, while an absolute necessity, could become more problematic as researchers debate how much replication is enough, especially in the case of small effect sizes. Perhaps in genetic epidemiology, replication may be a continuous process without end. In research on medical interventions, too much replication is unacceptable because it exposes people to documented risks from harmful interventions or withholds benefits from effective interventions. In genetic epidemiology, the downside of excess replication lies in the opportunity costs-research funds and investigator efforts that could be better applied to other endeavours. Even accumulated evidence from a large number of studies may have modest credibility, and better and larger studies may still be needed. The cost of replicating associations with individual genetic variants emerging as candidates from a GWA study will be considerably less costly than the GWA study itself. Certainly, an open model for sharing of individual level data in GWA studies-as we are beginning to see from the NIH-sponsored Genetic Association Information Network (GAIN) initiative 58 and the Wellcome Trust-sponsored Wellcome Trust CaseControl Consortium (WTCCC) consortium 59 -may help the validation/replication process by enhancing transparency and minimizing selective reporting biases. 'Protection from bias' is difficult to assess. Most known biases in epidemiology cause spurious associations that can easily mimic a true small effect size. Biases introduced by genotyping 
Conclusions
In evaluating associations between genetic variants and common complex diseases, we should fully expect biologically meaningful associations with small effects. The usual criteria for grading the evidence and for causal inference need to be adapted and modified. As part of the HuGENet 'road map', an ongoing effort has been made to streamline and operationalize criteria for genetic associations with various common diseases. Because of the lack of clinical or public health utility of these weak associations for genetic testing, many may dismiss such findings as hype, focusing on the obvious methodological issues that plague genetic association studies. We do not think this should be discouraging. Weak associations will be the norm rather than the exception and in the current era of genomewide association studies, we have the opportunity to develop a validated and continuously updated 'knowledge base' on the relationship between genetic factors and human diseases. Studying bias and false positive findings will be very informative and useful. The next few years will provide a crucial window of opportunity to develop methods and standards for measuring, validating and interpreting genetic associations. The simple answer to 'are we there yet?' may be 'no' for years to come. Ultimately, the promise of the Human Genome Project rests on our ability to accurately characterize the relationship between genetic variation and human disease and use this information for the benefit of population health.
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